Objective: To evaluate the factors predicting the time to progression to castration-resistant in metastatic prostate cancer under Androgen Deprivation Therapy (ADT) in our center. Patients and Methods: This is a retrospective, descriptive, analytical study in a single center over a period of 2 years. It has interest patients followed for metastasized prostate cancer under ADT. The parameters studied were: epidemiological, clinical, paraclinical, prostate specific antigen (PSA) nadir, time to nadir (TTN) and their link with the castration resistance. Results: The frequency of castration resistant prostate cancer was 28 patients per year. The mean age was 70.4 ± 7.9 years. An ECOG score ≥ 3 was more common as was the cT2c stage. The median of the initial total PSA was 489.6 ng/ml (203.3; 1653.2). All patients had adenocarcinoma. The International Society of Urological Pathology (ISUP) 1 was more frequent. Bone metastases were more frequent. The medians of nadir, TTN and the castration resistance were 19.3 ng/ml (3.7; 102.1), 5.5 months (3; 9) and 11 months (6; 15.3), respectively. The Eastern Cooperative Oncology Group (ECOG) score, clinical stage, metastatic site, the nadir and its TTN influenced the DSR. Age, lymph node involvement, initial total PSA and Gleason score did not influence the castration resistance. Conclusion: ADT should be initiated as soon as possible before an attack of general and/or clinical stage advanced to delay resistance. A drilling should be associated with this hormone therapy as much as possible because of its gain on resistance.
Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254
Fall, B., Tengue, K., Sow, Y., Sarr, A., Thiam, A., Mohamed, S., et al. (2012) Place de la pulpectomie bilatérale dans la suppression androgénique pour cancer de la prostate. Progrès en Urologie, 22, 344-349. https://doi.org/10.1016/j.purol.2011.12.005
Gueye, S.M., Jalloh, M., Labou, I., Niang, L., Kane, R. and Ndoye, M. (2004) Profil clinique du cancer de la prostate au Sénégal. African Journal of Urology, 10, 203-207.
Huggins, C. and Hodges, C.V. (1972) Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. CA: A Cancer Journal for Clinicians, 22, 232-240. https://doi.org/10.3322/canjclin.22.4.232
Khoury, S. (2012) Cancer de la prostate Hormono-indépendant. Progrès en Urologie, 1202, 7-18.
Crawford, E.D., Petrylak, D. and Sartor, O. (2017) Navigating the Evolving Therapeutic Landscape in Advanced Prostate Cancer. Urologic Oncology, 35, 1-13. https://doi.org/10.1016/j.urolonc.2017.01.020
Rozet, F., Hennequin, C., Beauval, J.-B., Beuzeboc, P., Cormier, L., Fromont, G., et al. (2016) Recommandations en onco-urologie 2016-2018 du CCAFU: Cancer de la prostate. Progrès en Urologie, 27, 95-144. https://doi.org/10.1016/S1166-7087(16)30705-9
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013) Cancer de la prostate: Quelle prise en charge au Sénégal? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
Higano, C.S. and Crawford, E.D. (2011) New and Emerging Agents for the Treatment of Castration-Resistant Prostate Cancer. Urologic Oncology, 29, 1-8. https://doi.org/10.1016/j.urolonc.2011.08.013
Wade, C. and Kyprianou, N. (2018) Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences, 19, 904. https://doi.org/10.3390/ijms19030904
Rigaud, J., Le Normand, L., Karam, G., Glémain, P., Buzelin, J.-M. and Bouchot, O. (2002) Facteurs pronostiques du cancer de la prostate traité par hormonothérapie de première intention. Progrès en Urologie, 12, 232.
Mulders, P.F., Dijkman, G.A., Fernandez del Moral, P., Theeuwes, A.G. and Debruyne, F.M. (1990) Analysis of Prognostic Factors in Disseminated Prostatic Cancer. An Update. Dutch Southeastern Urological Cooperative Group. Cancer, 65, 2758-2761. https://doi.org/10.1002/1097-0142(19900615)65:12 3.0.CO;2- 6
Emrich, L.J., Priore, R.L., Murphy, G.P. and Brady, M.F. (1985) Prognostic Factors in Patients with Advanced Stage Prostate Cancer. Cancer Research, 45, 5173-5179.
Angwafo, F.F. (1998) 3rd. Re: Prostate Cancer in Nigerians: Facts and Nonfacts. Journal of Urology, 160, 135. https://doi.org/10.1016/S0022-5347(01)63068-4
Chodak, G.W., Vogelzang, N.J., Caplan, R.J., Soloway, M. and Smith, J.A. (1991) Independent Prognostic Factors in Patients with Metastatic (Stage D2) Prostate Cancer. The Zoladex Study Group. JAMA, 265, 618-621. https://doi.org/10.1001/jama.1991.03460050072023
Oosterlinck, W., Mattelaer, J., Casselman, J., Van Velthoven, R., Derde, M.P. and Kaufman, L. (1997) PSA Evolution: A Prognostic Factor during Treatment of Advanced Prostatic Carcinoma with Total Androgen Blockade. Data from a Belgian Multicentric Study of 546 Patients. Acta Urologica Belgica, 65, 63-71.
Oosterlinck, W., Mattelaer, J., Derde, M.P. and Kaufman, L. (1995) Prognostic Factors in Advanced Prostatic Carcinoma Treated with Total Androgen Blockade. Flutamide with Orchiectomy or with LHRH Analogues. A Belgian Multicentric Study of 546 Patients. Acta Urologica Belgica, 63, 1-9.
Jørgensen, T., Kanagasingam, Y., Kaalhus, O., Tveter, K.J., Bryne, M., Skjørten, F., et al. (1997) Prognostic Factors in Patients with Metastatic (Stage D2) Prostate Cancer: Experience from the Scandinavian Prostatic Cancer Group Study-2. Journal of Urology, 158, 164-170. https://doi.org/10.1097/00005392-199707000-00052
Robinson, D. (2008) Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase. Journal of Urology, 179, 117-123. https://doi.org/10.1016/j.juro.2007.08.132
Johansson, J.E., Andersson, S.O., Holmberg, L. and Bergström, R. (1991) Prognostic Factors in Progression-Free Survival and Corrected Survival in Patients with Advanced Prostatic Cancer: Results from a Randomized Study Comprising 150 Patients Treated with Orchiectomy or Estrogens. Journal of Urology, 146, 1327-1333. https://doi.org/10.1016/S0022-5347(17)38081-3
Sine, B., Bagayogo, N.A., Thiam, A., Sarr, A., Zakou, A.R., Faye, S.T., et al. (2016) Cancers de la prostate de score de Gleason supérieur ou égal à 8: Evaluation de la survie des patients. African Journal of Urology, 22, 243-248. https://doi.org/10.1016/j.afju.2016.01.011
Gagnat, A., Larré, S., Fromont, G., Pirès, C., Doré, B. and Irani, J. (2011) La survie est associée au délai d’atteinte du PSA nadir (DAN) et au ratio DAN/valeur nadir après suppression androgénique pour cancer de prostate. Progrès en Urologie, 21, 341-348. https://doi.org/10.1016/j.purol.2010.09.024
Halabi, S., Kelly, W.K., Ma, H., Zhou, H., Solomon, N.C., Fizazi, K., et al. (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 34, 1652-1659. https://doi.org/10.1200/JCO.2015.65.7270
Choueiri, T.K., Xie, W., D’Amico, A.V., Ross, R.W., Hu, J.C., Pomerantz, M., et al. (2009) Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen-Deprivation Therapy. Cancer, 115, 981-987. https://doi.org/10.1002/cncr.24064
Nayyar, R., Sharma, N. and Gupta, N.P. (2010) Prognostic Factors Affecting Progression and Survival in Metastatic Prostate Cancer. Urologia Internationalis, 84, 159-163. https://doi.org/10.1159/000277592
Hori, S., Jabbar, T., Kachroo, N., Vasconcelos, J.C., Robson, C.N. and Gnanapragasam, V.J. (2011) Outcomes and Predictive Factors for Biochemical Relapse Following Primary Androgen Deprivation Therapy in Men with Bone Scan Negative Prostate Cancer. Journal of Cancer Research and Clinical Oncology, 137, 235-241. https://doi.org/10.1007/s00432-010-0877-9